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Per Øyvind Enger1, Anne Simonsen3 and Martha Chekenya1
BACKGROUND: Resistance to temozolomide (TMZ) is due in part to enhanced DNA repair mediated by high expression of O6-
methyl guanine DNA methyltransferase (MGMT) that is often characterised by unmethylated promoter. Here, we investigated pre-
treatment of glioblastoma (GBM) cells with the 26S-proteasome inhibitor bortezomib (BTZ) as a strategy to interfere with MGMT
expression and thus sensitise them to TMZ.
METHODS: Cell lines and patient GBM-derived cells were examined in vitro, and the latter also implanted orthotopically into NOD-
SCID C.B.-Igh-1b/lcrTac-Prkdc mice to assess efficacy and tolerability of BTZ and TMZ combination therapy. MGMT promoter
methylation was determined using pyrosequencing and PCR, protein signalling utilised western blotting while drug biodistribution
was examined by LC-MS/MS. Statistical analysis utilised Analysis of variance and the Kaplan–Meier method.
RESULTS: Pre-treatment with BTZ prior to temozolomide killed chemoresistant GBM cells with unmethylated MGMT promoter
through MGMT mRNA and protein depletion in vitro without affecting methylation. Chymotryptic activity was abolished, processing
of NFkB/p65 to activated forms was reduced and corresponded with low MGMT levels. BTZ crossed the blood–brain barrier,
diminished proteasome activity and significantly prolonged animal survival.
CONCLUSION: BTZ chemosensitized resistant GBM cells, and the schedule may be amenable for temozolomide refractory patients
with unmethylated MGMT promoter.
British Journal of Cancer (2019) 121:545–555; https://doi.org/10.1038/s41416-019-0551-1
BACKGROUND
Glioblastoma (GBM) is the most frequent and lethal primary brain
malignancy in adults. Standard therapy, including surgery and
temozolomide (TMZ), administered concomitantly with fractio-
nated ionising radiotherapy extends median survival to only
14.6 months.1 Thus, an urgent, unmet need for strategies that can
overcome chemoresistance grows as society ages, and GBM-
reported incidence and/or diagnosis increases.
TMZ is an alkylating chemotherapy that generates toxic
O6-methylguanine DNA adducts. During replication, these adducts
become irreversibly bound by the suicide DNA repair enzyme, O6-
methyl guanine (O6-MeG) DNA methyltransferase (MGMT), which is
then ubiquitinated and targeted for degradation.2 MGMT-
mediated DNA repair is a major cause of treatment failure,3,4 and
thus promoter methylation status in patient tumours has become a
predictive biomarker for response to TMZ. The median survival of
patients with methylated MGMT versus unmethylated promoter in
tumours was 21.7 versus 12.7 months after TMZ chemoradiation.4
Transcriptional regulation of MGMT expression is complex, and
several factors, including SP-1, AP-1, CEBP, HIF-1α and NFκB, have
been implicated. NFκB signals downstream of PI3K/AKT signalling,
which is constitutively activated in many GBMs due to mutations
in the tumour suppressor PTEN.5,6 NFκB binds the MGMT promoter
at two sites and regulates its expression via p65 (RelA).7 Activation
of NFκB is dependent on proteasomal activity, which catalyses the
proteolysis of an inactive precursor into transcriptionally active
p50/p65 subunits, as well as the destruction of the inhibitory
factor IκBα.8,9 Thereafter, p65 translocates to the nucleus and
MGMT is transcribed. Targeting the proteasomal pathway might
thus diminish NFκB transcription-dependent MGMT expression
through retention of the inactive complexes in the cytoplasm.10
Bortezomib (BTZ, Velcade) is a proteasome inhibitor that
reversibly blocks the chymotryptic-like activity of the β5 and
β1 subunits of the 20S proteasome. The drug is approved for the
treatment of multiple myeloma and mantle cell lymphoma,11 and
is an attractive candidate for other malignancies. For GBM, BTZ has
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been shown to reduce levels of MGMT in T98G cells in vitro, which
harbour a partially unmethylated MGMT promoter and further
shown to induce apoptosis in these cells when administered prior
to TMZ12,13 associated with activation of NFκB, MAPK, STAT3 and
HIF-1α pathways. However, these studies were performed using
homogeneous cell lines (U87 and T98G) in short-term cell viability
assays after 24 h with considerably high doses (>100 nM) of
bortezomib.12–14 In investigating the involvement of the NFkB/p65
pathway, these studies did not use phosphor-site-specific
antibodies, challenging interpretation of activation of the path-
way. Neither preclinical studies in vivo on heterogeneous patient-
derived GBM cells with an unmethylated MGMT promoter nor
indeed clinical trials have investigated BTZ in sensitisation
schedule for Temozolomide, as we propose in this paper. Previous
preclinical studies administered BTZ as monotherapy in tumours
implanted at ectopic sites.15,16 Several clinical studies investigated
BTZ as an add-on therapy to low doses of TMZ17 combined with
radiotherapy,18 bevacizumab,17 Tamoxifen19 or HDAC inhibitors,20
or as monotherapy21 and all deemed it safe and tolerated.19,21,22 A
recent phase II study reported some survival benefit23 after
prolonged treatment.
Depletion of MGMT, using the artificial substrate O6-benzylgua-
nine, has been shown to sensitise tumour cells to alkylating
chemotherapy.24 We thus, hypothesised that BTZ pre-treatment
may sensitise chemoresistant GBM cells to TMZ. We used several
patient-derived tumour cells in vitro and in vivo and treated the
animals with human equivalent doses of both drugs for added
clinical relevance. NOD-SCID mice permit engraftment of primary
cells and the resultant patient-derived GBM xenografts at
orthotopic sites demonstrate similar biological characteristics,
molecular genetics and therapy responses of the patient-derived
parental tumour.25,26 We tested the in vivo efficacy of pre-
treatment with BTZ followed by TMZ in resistant and sensitive
patient-derived tumours in vivo. We investigated responses to two
human equivalent TMZ doses and could demonstrate that 164
mg/m2 that was closest to the 200mg/m2 administered to
recurrent patients was most effective as it (i) prolonged
progression free survival and (ii) overall survival in animals bearing
GBM with unmethylated MGMT promoter. We also demonstrated
that BTZ administered 48 h prior to this effective TMZ dose crosses
the blood–brain barrier (BBB), depleted MGMT mRNA levels and
attenuated proteasome activity in vivo, thus accounting for
restored TMZ sensitivity and prolonged animal survival. Boos-
ter BTZ+TMZ combinations during follow-up after first MRI
evidence of relapse may further extend overall survival in the
BTZ+TMZ164mg/m2 treatment group. Our preclinical study is the
first in vivo study investigating efficacy of a sequential, sensitisa-
tion treatment schedule with Bortezomib and Temozolomide. Our
extensive characterisation of potential toxicity through analyses of
liver function, bone marrow-derived cells, coagulation profiles and
animal weights proved the treatment safe and tolerated,
consistent with patient clinical trials.19,21–23 Our results suggest
that such a sensitisation schedule may be of clinical benefit for
GBM patients with unmethylated MGMT promoter.
METHODS
A detailed description of the methods used in the present study
can be found in Supplementary Information.
Ethics statement
Approval for the collection of primary human tumour samples into
a centralised biobank (REK Vest 013.09/20879) with patients´
written informed consent and approval for use in experimental
procedures in the project (REK2018/71) was obtained from the
REK Vest regional ethical committee and the Norwegian Data
Protection Agency. The animal study protocols were approved by
The Norwegian Animal Research Authority (Oslo, Norway, FOTS ID
9460) in accordance with the European Convention for the
Protection of Vertebrates Used for Scientific Purposes [Scientific
Procedures] Act 1986, as well as the ARRIVE guidelines.27
Isolation of primary glioma cells
P3, 2012–018 and BG7 patient-derived GBM cells were expanded
from biopsies obtained from patients undergoing tumour resec-
tion at the neurosurgery department (Haukeland University
Hospital; Bergen, Norway). These cells, as well as long-term cell
lines (U87, T98G, HF66 and A172), were propagated as monolayers
in Dulbecco’s modified eagle medium (DMEM, Sigma-Aldrich; St.
Louis, MO, USA) supplemented with 10% foetal bovine serum,
non-essential amino acids, 100 U/mL penicillin/streptomycin and
400 μM L-glutamine (complete medium; all Cambrex; East
Rutherford, NJ, USA) at 37 °C in a humidified atmosphere of 5%
CO2. Patient-derived cells and cell lines were authenticated by
short tandem repeat loci (STR) analysis as described in Supple-
mentary Methods. Profiles from patient-derived cells were
compared with those from the original parental biopsy (P3,
2012–018 and BG7), and cell lines were authenticated against the
profiles from previously fingerprinted stocks or manufacturer
provided profiles, e.g., ATCC repository (T98G, A172 and U87) or
manufacturer (NHA) Applied Biological Materials Inc. (Richmond,
BC, Canada).
Drugs
Temozolomide (TMZ, 2706/50, Tocris Bioscience; Bristol, UK) and
MG-132 (M7449, Sigma-Aldrich) were dissolved in DMSO and
stored at –20 °C. Bortezomib (BTZ, Velcade®, 576415, Janssen;
Lysaker, Norway) and Carfilzomib (PR-171; Haukeland University
Hospital pharmacy, Bergen, Norway) were dissolved in 0.9% v/v
sodium chloride and stored at –80 °C and –20 °C, respectively. The
human equivalent doses (HED) were calculated as previously
reported;28 mouse 25mg/kg and 50mg/kg TMZ doses are
equivalent to human doses of 84mg/m2 and 164 mg/m2,
respectively. We used BTZ 0.5 mg/kg in vivo, which is equivalent
to a human dose of 1.3 mg/m2.
Clonogenic survival assay
Cells were seeded at plating efficiency (1000 cells/well) in six-well
plates and exposed to TMZ (72 h: 12.5–250 μM) or BTZ (48 h:
5–25 nM) as monotherapy or in combination. After the treatment
period, culture medium was replaced with fresh medium followed
by further observation for 14 days. After 14 days, colonies were
fixed, stained in 6% glutaraldehyde/0.5% Crystal violet and
counted as previously described.29 Surviving fractions were
calculated from experiments performed in triplicate, and data
represents at least three independent experiments.
Intracranial implantation of glioblastoma spheroids
P3 and BG7 GBM cells were propagated in vitro in the Neural Basal
(NB) medium (Invitrogen, Hämeenlinna, Finland) supplemented with
1% GlutaMAX (Invitrogen, Carlsbad, CA, USA), 2% B-27 (Invitrogen),
5% penicillin–streptomycin, 10mg/ml epidermal growth factor and
fibroblast growth factor (PeproTech SE, Stockholm, Sweden) at 37 °C
in a humidified atmosphere of 5% CO2. For in vivo experiments,
standardised neurospheres containing 104 cells/sphere were estab-
lished by centrifuging cells in a CorningTM Clear Polystyrene V
shaped-bottom 96-well plates in 0.5% v/v methylcellulose-NB for 2 h
at 2250 rpm and 33 °C. Spheroids were cultured for 1 week
in the incubator at 37 °C and 5% CO2, and media was changed
at day 4. P3 and BG7 tumour spheroids (five per animal)
were implanted intracranially into male and female 7-week-old
(20 g) severe combined immunodeficient (NOD-SCID) mice
(C.B.-Igh-1b/lcrTac-Prkdc) (Janvier Labs; Le Genest-Saint-Isle, France)
after anaesthetic with Servoflurane (Abbott Laboratories Ltd.,
Maidenhead, UK) as specified in Supplementary Information and
previously described.30 After surgery, animals were allowed to
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recover from anaesthesia in a pre-warmed incubator and adminis-
tered Temgesic (0.05mg/kg, intraperitoneal injection, Indivior UK
limited, Berkshire, UK) as analgesia for 3 days. The treatment
schedule is illustrated in Fig. 3a. Both sexes were used in order to rule
out hormonal effects on tumour growth and reduce pressure on
animal breeding for experimental purposes. The animals were
housed in pairs in internally ventilated, closed cages (IVC) with
standard bedding (NESTPAK™, Datesand, Manchester, UK). The
animals were kept in an isolation facility at 25 °C (55% relative
humidity) on a standard 12 h night and day cycle in a specific
pathogen-free environment, and fed a standard pellet chow and
provided tap water ad libitum. Animal husbandry protocols were
followed where animals were monitored daily according to humane
endpoint guidelines by experimental staff and independently, by
animal husbandry staff, including inhouse veterinarian. Mice were
sacrificed by CO2 inhalation and decapitation when neurological
symptoms of rotational behaviour, reduced activity, grooming and or
upon 20% body weight loss. Further information can be found in
Supplementary Material.
For calculation of sample sizes, we used the formula: n= ((2 ×
(s)2)/(gr1− gr2)2) × F(a, b)) (http://www.stat.ubc.ca/~rollin/stats/
ssize/n2.html), where Gr1= 9 represents the average survival in
weeks for control animals with the same tumour type; Gr2= 10.6,
minimum average survival in weeks, which we believe is necessary
for the survival to be of clinical relevance, sigma (s)= 1.0, standard
deviation of the average survival of control animals with the same
tumour type. A two-sided T test was chosen, where a= p <
0.05 significance level, b= 0.80, power for this experiment. With
this power calculation, we determined that n= 7 animals per
group were required to show a significant difference of at least
1.4 weeks (10 days) between the control group and the
treatment group.
LC-MS-MS assay for detection of bortezomib in mouse brain tissue
In all, 250 µl of acetonitrile (Honeywell, Seelze, Germany),
containing bortezomib-d8 (Toronto Research Chemicals, Tor-
onto, Canada) as an internal standard, and 250 µl of a 1%
aqueous solution of formic acid (Sigma-Aldrich, Steinheim,
Germany) were added to cryopreserved mouse brain tissue.
The samples were then homogenised in a Tissuelyser ball mill
from Qiagen (Crawley, UK), thereafter sonicated for 5 min and
centrifuged for 10 min at 2 °C. In total, 100 µl of the supernatant
was removed and evaporated to dryness under flowing
nitrogen. In all, 100 µl of a 1% v/v formic acid was used for
reconstitution, and the samples were then subjected to
liquid–liquid extraction by adding 700 µL of methyl tert-butyl
ether (Sigma-Aldrich, Steinheim, Germany). Overall, 600 µl of the
supernatant was evaporated to dryness and reconstituted in
100 µl of acetonitrile: 0.01% formic acid (50:50, v/v) and analysed
on an Acquity UPLC system connected to a Xevo TQ-S tandem
mass spectrometer (Waters, Milford, MA, USA). The compounds
were separated on a Waters BEH C18 column (50 × 2.1 mm, 1.7 -
µm particle size), which was developed by gradient elution over
14 min using water:acetonitrile (9:1, v/v) as a weak mobile phase
and acetonitrile as a strong mobile phase. Bortezomib was
detected in the positive mode by using the 367.1 > 226.0
transition as quantifier, and the 367.1 > 207.9 as qualifier. The
ratio between quantifier and qualifier was calculated to check
the purity of the chromatographic peaks. Similarly, the 375.2 >
233.9 and 375.2 > 215.1 transitions were used for bortezomib-
d8. Brain tissue from untreated mice was used for calibration
after adding known amounts of bortezomib standard (Toronto
Research Chemicals) to the precipitation solution. Final con-
centrations of bortezomib were adjusted for the weight of each
brain sample, which ranged from 11 mg to 36 mg. Bortezomib
was stable in acetonitrile: aqueous formic acid for 48 h at
room temperature (99 ± 16.8%) and during five freeze–thaw
cycles (108 ± 13.3%). They were also stable for one hour after
adding the precipitation solution and for 24 h in the auto-
sampler (95 ± 10.8%).
Statistical analysis
Survival outcome of tumour-bearing mice was analysed using the
Kaplan–Meier method with the Mantel–Cox log-rank test.31 One-
way ANOVA and two-way ANOVA were used to analyse data with
one dependent variable, or two or more dependent variables,
compared in two or more groups. Bonferroni or Tukey’s post hoc
correction for multiple testing was used. Descriptive statistics were
reported as the mean ± standard error of the mean (S.E.M.) unless
otherwise stated. Two-sided P-values < 0.05 were considered
significant (shown as *P < 0.05, **P < 0.01, ***P < 0.001, and ****P
< 0.0001). All graphs represent the mean ± S.E.M. of at least three
independent experiments. All statistical analyses were performed
in Stata version 13.1 (College Station, TX, USA) or GraphPad Prism
v6.07 (La Jolla, CA, USA).
RESULTS
GBM cells are most sensitive to BTZ
We first investigated the responses of patient-derived GBM
primary cells and cell lines of different genetic backgrounds
(Supplementary Table I) to monotherapy with the alkylating agent
TMZ. We began by confirming the tumour cells´ bonafide identity
by short tandem repeat loci (Supplementary Information). P3,
T98G and HF66 were the most TMZ-resistant GBM cell lines, while
A172, BG7, 2012–018, U87 and control normal human astrocytes
(NHA) were the most sensitive (Fig. 1a, b). TMZ sensitivity was
consistent with the methylation status of the MGMT promoter (P <
0.0001, Fig. 1a–c; Supplementary Table I). We then investigated
the cytotoxic efficacy of BTZ compared with other proteasome
inhibitors carfilzomib and MG-132 in these same cell lines
(Supplementary Table I; Fig. 1d). P3 cells were more sensitive to
BTZ compared with carfilzomib (P < 0.05) or MG-132 (P < 0.01),
likewise 2012–018 cells for both drugs (P < 0.001) where IC50 doses
for BTZ at 48 h were significantly lower than for carfilzomib or MG-
132 (Fig. 1d; Supplementary Table I). Long-term cell lines were also
most responsive to BTZ after 48 h (P < 0.01, Fig. 1e; Supplementary
Table I). However, clonogenic survival analysis following BTZ
treatment revealed 10 nM (range 8–12 nM) as the physiologically
relevant IC50 dose in the cell types tested (Fig. 1f; Supplementary
Table I).
BTZ sensitises GBM cells to TMZ chemotherapy through depletion
of MGMT
MGMT protein levels were upregulated with increased TMZ dose
and treatment duration by fourfold to sixfold in P3 cells where the
MGMT promoter was unmethylated (P < 0.0001, Fig. 1g, k). Protein
levels were only gradually reduced with a protracted treatment
period of 72–120 h in T98G cells with a partially unmethylated
MGMT promoter (Fig. 1i). In contrast, BTZ monotherapy at 10 nM
efficiently suppressed MGMT protein and mRNA levels by 80 ±
18.8% in P3 cells (Fig. 1h, k, l, P < 0.01 and P < 0.0001, respectively),
and decreased MGMT protein by 70% in T98G (Fig. 1j) after 48 h.
However, treatment with low dose BTZ for 24 h did not lead to
decreased MGMT protein expression in P3 or T98G cells (Fig. 1h, j).
In contrast to TMZ, cells were sensitive to BTZ treatment, which
led to reduced levels of MGMT protein after 48 h, but not 24 h,
indicating that this time point might be optimal for combination
treatment.
Because MGMT mRNA and protein levels were decreased under
BTZ treatment, we investigated whether BTZ pre-treatment might
sensitise GBM cells to TMZ when MGMT levels are low. Pre-
treatment with 10 nM BTZ for 48 h followed by TMZ treatment
significantly reduced the survival fraction of P3 and T98G GBM
cells (unmethylated MGMT promoter) compared with TMZ
monotherapy (P < 0.01 to P < 0.0001, Fig. 1m, n, respectively)
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and untreated controls (all P < 0.0001), but not BTZ alone (P > 0.05,
Fig. 1m, n). In contrast, BG7 patient-derived GBM cells (methylated
MGMT promoter) were highly sensitive to either TMZ or BTZ (P <
0.0001, Fig. 1o), and were thus not further sensitised under
combination treatment. These results provided proof-of-concept
for our selected focus of combination treatment on resistant
tumours with unmethylated MGMT promoter. The IC50 dose of
TMZ in combination with BTZ in P3 and T98G cells was reduced to
half of the IC50 dose of either drug in monotherapy (Fig. 1m, n).
MGMT protein and mRNA levels were also decreased in P3 under
combined treatment compared with TMZ monotherapy (Fig. 1k, l
and Fig. 2a, b). Combination treatment also reduced MGMT
protein by 30–40% in T98G (Fig. 2b), indicating that low dose BTZ
synergised with TMZ in killing resistant cells, potentially through
suppression of MGMT mRNA and protein expression.
Decreased nuclear NFkB/p65 transcription factor is coincident with
MGMT protein loss
To elucidate potential mechanisms for the loss of MGMT mRNA
and protein in the presence of BTZ, we first confirmed that BTZ
blocked the chymotryptic activity of the 20S proteasome (Fig. 2c).
Chymotryptic activity remained unchanged at 48 h in TMZ-treated
P3 cells relative to controls. In contrast, the catalytic activity of β5
and β1 subunits was significantly inhibited whether cells were
treated with BTZ alone for 24 and 48 h or combined with TMZ (P <
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Fig. 1 GBM cells are sensitive to BTZ due to depletion of MGMT protein and mRNA. (a) Mean % ± standard error of the mean (S.E.M.) survival
of control NHA, glioma cell lines and patient-derived cells treated with TMZ for 72 h using clonogenic assays. (b) Mean ± S.E.M. clonogenic
survival on IC50 doses (µM) of TMZ in MGMT methylated (M) or unmethylated (U) GBM cells. (c) Ethidium bromide-stained agarose gel showing
amplified DNA fragments corresponding to MGMT promoter methylation status in NHA and glioma cells. For positive control of unmethylated
MGMT promoter HCC1569, breast cancer cells were used (Supplementary Fig. 3). MW: 93 bp, unmethylated; and 81 bp, methylated. (d) Mean ±
S.E.M. viability on IC50 doses (nM) of BTZ, carfilzomib or MG-132 after 48 h treatment of P3, 2012-018 and NHA. (e) Mean ± S.E.M. viability on
IC50 doses (nM) of BTZ after 24 or 48 h treatment of NHA, U87 and T98G. (f) Mean % ± S.E.M. survival of tumour cells treated with BTZ for 48 h
using clonogenic assays. Western blots of MGMT protein levels after TMZ dose and time for (g) P3, (i) T98G cells, and after BTZ treatment for
(h) P3, (j) T98G, 24 and 48 h. % relative to control of MGMT (k) protein and (l) mRNA expression from P3 GBM cells after treatment. Clonogenic
surviving fractions of (m) P3, (n) T98G and (o) BG7 cells after treatment. Each experiment was performed in triplicate, and the data represent
the mean ± S.E.M. of at least three independent experiments, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
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was restored after the period spanning combination BTZ for 48 h
and TMZ treatment for further 48 h.
We then assessed protein levels of transcription factors under
proteasome blockade using an activated transcription factor
protein array. NFκB, as well as peroxisome proliferator-activated
receptor (PPAR) and Ying Yang-1 (YY1), accumulated in response
to BTZ alone or in combination with TMZ (Fig. 2d). Further
examination of NFκB subunits using total and nuclear protein
extracts indicated that although phosphorylated p65 remained
unchanged in total protein lysates under all treatments relative to
controls, BTZ led to reduced levels of phosphorylated/activated
p65 in the nucleus (Fig. 2e, f). Total and nuclear levels of MGMT
protein were also reduced in the presence of BTZ, indicating a
potential decrease in p65-mediated transcription of the gene
(Fig. 2d–f). Pyrosequencing of the MGMT promoter confirmed that
only a few CpG islands were methylated in the MGMT promoter of
P3 cells, which did not change after treatment with either BTZ
alone or combination BTZ+TMZ treatment (Fig. 2g, h).
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Fig. 2 Decreased NFκB transcription is associated with reduced MGMT protein levels. MGMT protein levels after combination BTZ+TMZ
treatment in (a) P3 and (b) T98G cell lines. GAPDH was used as a loading control. Band intensity expressed as a ratio after normalisation to
GAPDH. (c) Chymotryptic activity of the β1 and β5 subunits measured as relative fluorescence units (RFU/380/460 nm) of fluorophore 7-amino-
4-methylcoumarin in cells treated as indicated. (d) Fold change in transcription factor activity in nuclear extracts from P3 cells. NFκB/
p65 subunit levels in P3 cell extracts from (e) total protein, and (f) nuclear fraction after treatment, as indicated. (g) Representative peak
heights and nucleotide disposition order (NDO) within MGMT promoter CpG region (h) % MGMT promoter methylation in P3 cells after
treatment. Each experiment was performed in triplicate, and the data represent the mean ± S.E.M. of at least three independent experiments,
*P < 0.05 and ****P < 0.0001
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Combination treatment rapidly shrinks tumour growth and
prolongs survival of mice
NOD-SCID mice were orthotopically implanted with GBM cells to
generate xenograft models to investigate the efficacy of combina-
tion treatment in vivo. We first examined treatment in P3 xenografts
with unmethylated MGMT promoter. The schedule for treatment is
shown in Fig. 3a. Tumours treated with vehicle or BTZ monotherapy
progressed rapidly and killed their hosts within 41 days post
implantation (Fig. 3b, c and f). The tumours had hypointense cores
and high signal, ring-enhancing edges on T1-weighted MRI with
contrast that was indicative of florid tumour angiogenesis (Fig. 3b).
Tumour population doubling time was significantly prolonged by
2.9 days already at day 11 post BTZ+TMZ 164mg/m2 treatment
compared with TMZ 164mg/m2 (7.8 days vs. 4.9 days, respectively,
P < 0.05), and by 2.3 days compared with BTZ+TMZ 82mg/m2
(7.8 days vs. 5.5 days, P < 0.05; data not shown).
After TMZ 82mg/m2 treatment was completed at day 49,
tumours progressed by day 61 (Fig. 3b, d), whereas TMZ 164mg/
m2 treatment reduced tumour volumes slowly compared with
TMZ 82mg/m2 (P < 0.001, Fig. 3b, d). BTZ+TMZ 82mg/m2 treated
tumours relapsed upon discontinuation of treatment at day 49,
although they were significantly smaller than tumours treated
with TMZ 82mg/m2 at all time points (P < 0.001, Fig. 3d). Tumours
from animals treated with BTZ+TMZ 164mg/m2 remained small
throughout the treatment and follow-up (P < 0.0001, compared
with TMZ 82mg/m2, P < 0.05 compared with TMZ 164mg/m2 and
P < 0.05 compared with BTZ+TMZ 82mg/m2, Fig. 3b, d) and were
abolished entirely in 30% of cases (Fig. 3e). Thus, the combination
regimen BTZ+TMZ 164mg/m2 significantly prolonged survival
(log-rank 39.18, df= 5, P < 0.0001, Fig. 3f). 16% of BTZ+TMZ 164
mg/m2 treated animals were alive at day 138, the termination
point of the experiment, and median survival was 114 days
compared with 100 days with TMZ 164mg/m2 (P= 0.0063) or
93 days with BTZ+TMZ 82mg/m2 (P= 0.0012, Fig. 3f).
We investigated efficacy in a second xenograft model devel-
oped with BG7 cells with methylated MGMT promoter. We found
that animals treated with vehicle or BTZ monotherapy developed
large diffusely enhancing tumours (Fig. 3g, h) that progressed
rapidly and killed their hosts within 69 and 74 days, respectively
(Fig. 3i). Animals treated with TMZ 164mg/m2 survived a median
of 149 days compared with 69 and 74 days of control and BTZ
treated animals (P < 0.0001, respectively), while combination BTZ
+TMZ 164mg/m2 extended most survival of animals to 184 days
(log rank 27.59, df= 3, P < 0.001, Fig. 3g–i). This combination
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Fig. 3 Combination BTZ+TMZ 164mg/m2 treatment suppresses tumour growth and prolongs survival. (a) Schematic outline showing tumour
implantation, treatment schedule and frequency of MRI monitoring. (b) Axial contrast enhanced T1-weighted longitudinal MRI follow-up of
the same P3-bearing animal from each treatment group as indicated in days. (c) Mean ± S.E.M. of 3D measured tumour volumes (mm3) from
T1-weighted with contrast images of (c) all P3 animals in vehicle control and BTZ 1.3 mg/m2 groups (Student’s t test, **P < 0.01), and (d) all
animals in TMZ monotherapy or BTZ+TMZ combination as indicated. (e) Representative T1-weighted MRI with contrast of animals (n= 3) from
the BTZ+TMZ 164mg/m2 treatment group showing near complete tumour regression. (f) Kaplan–Meier curves showing percentage survival
in days. (g) Axial contrast enhanced T1-weighted longitudinal MRI follow-up of the same BG7 tumour-bearing animal from each treatment
group as indicated in days. (h) Mean ± SEM of BG7 tumour volumes (mm3) from T1-weighted as above. (i) Kaplan–Meier curves showing
percentage survival in days. One-way ANOVA with Bonferroni correction for multiple testing, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P <
0.0001
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BTZ+TMZ treatment decreases tumour angiogenesis and
proliferation
Tumours treated with vehicle or BTZ monotherapy were large,
highly cellular and exhibited both central and pseudopalisading
necrosis with pyknotic nuclei and mitotic figures (Fig. 4a). TMZ 82
mg/m2 and TMZ 164mg/m2 treated tumours had moderate-to-
low cell density dominated by giant nucleated tumour cells,
prominently fibrillary extracellular matrix and reduced mitotic
figures (Fig. 4a). BTZ+TMZ 82mg/m2 treated tumours were
consistently large, densely cellular with pseudopalisading necrosis
and pyknotic nuclei, whereas 50% (3/6) of
BTZ+TMZ 164mg/m2 treated tumours were small, fibrotic and
necrotic with only sparsely scattered tumour cells (Fig. 4a). As
degree of angiogenesis (measured by microvascular density) and
ki67 proliferation index is highly correlated with tumour growth,
we used these as surrogate markers that verify tumour growth
kinetics in the treated animals. Tumour cell proliferation, as
measured by the Ki67 labelling index, was significantly reduced
after BTZ+TMZ 164mg/m2 treatment compared with TMZ 164
mg/m2 (P < 0.05), BTZ+TMZ 82mg/m2 (P < 0.001), BTZ mono-
therapy (P < 0.01) and vehicle control (P < 0.05, one-way ANOVA,
Fig. 4b, d).
Tortuous microvascular proliferations were evident in control
and BTZ treated tumours, in contrast to moderate microvascular
density after TMZ 82mg/m2 and BTZ+TMZ 82mg/m2 treatment
(Fig. 4c). Tumours treated with BTZ+TMZ 164mg/m2 exhibited
markedly reduced angiogenic vascular density, compared with
BTZ+TMZ 82mg/m2 (P < 0.001), BTZ monotherapy or vehicle
control (P < 0.05, for both Fig. 4c, e). Expression of MGMT mRNA
was significantly reduced, by 83% in BTZ+TMZ 164mg/m2
compared with TMZ 164mg/m2 monotherapy treated tumours,
65% compared with BTZ+TMZ 82mg/m2 and 37% compared with
TMZ 82mg/m2 (P < 0.01 for all, Fig. 4f), indicating successful target
inhibition in vivo. Furthermore, β1 and β5 chymotryptic activity
was significantly reduced in BTZ-treated tumours compared with
vehicle controls (P < 0.01, Fig. 4g) and in combination treated
versus vehicle control (P < 0.05, Fig. 4g). The β1 and β5
chymotryptic activity was also reduced by ~25% in BTZ-treated
non-tumour-bearing brain tissue compared with healthy mouse
brain, (P < 0.05, Fig. 4h). There was no difference in chymotrytptic
activity of BTZ compared with combination treated tumours.
Biodistribution analyses (Fig. 5a–c) demonstrated that i.p.
administered BTZ does breach the BBB and could be detected
in greater concentrations in tumour tissue, and from animals killed
at earlier time points (P < 0.01, Fig. 5d). In healthy, non-tumour-
bearing mice, BTZ did cross the intact BBB, albeit with reduced
concentrations (P < 0.01, Fig. 5e). Taken together, BTZ+TMZ 164
mg/m2 treatment was therefore the most effective compared with
other treatment protocols, where BTZ crossed the BBB and
exhibited bioactivity in both tumour and non-tumour-bearing
brain tissue. It was well tolerated based on their liver function tests
(alanine aminotransferases and aspartate aminotransferases);
platelet counts and whole blood clotting times (Supplementary
Fig. 1A–D). Measures of platelet nadirs drop during treatment but
recovered rapidly to baseline (Supplementary Fig. 1A) between
treatment cycles, consistent with previous reports.32 GBM is
known to be prothrombotic rapid clotting time (Supplementary
Fig. 1B). BTZ prolonged clotting time at D1 (P < 0.0001 compared
with untreated control animals with tumour (ctrl + tumour); but
already after D2, the whole blood clotting time was normalised to
similar levels as in ctrl + tumour animals. As clotting factors are
partially contributed by the liver, we could show that liver function
(through enzymes, alanine and aspartate aminotransferase) was
unimpaired (Supplementary Fig. 1C, D) respectively. LC–MS/MS
characterisation of clotting profiles (Supplementary Fig. 1E) also
indicated that the treatment was safe and tolerated. In addition,
we measured daily the body weight of the mice treated with
one cycle vs. two cycles of BTZ. There was no treatment
induced severe weight loss and BTZ extended survival compared
to control in BG7 tumour bearing mice (Supplementary Fig.
2A–C). The body weight of all mice bearing P3 and BG7 tumours
was also not adversely affected by the treatment (Supplementary
Fig. 2D, E), confirming that the treatment was safe and tolerated.
Together, these findings further support a cooperative mechan-
ism in which TMZ 164mg/m2 and BTZ in potent salvo to promote
tumour cell death by perturbing proteasome function and
antioxidant regulation (Supplementary Fig. 1F, G).
DISCUSSION
Correlation of TMZ responsive and nonresponsive tumours to
MGMT promoter methylation status has implicated higher levels of
the enzyme in resistance to the drug. Here, we investigated a
strategy for depleting MGMT levels by treatment with the
proteasome inhibitor BTZ, before exposure to TMZ. We demon-
strated that pre-treating with BTZ for 48 h depleted MGMT
enzyme, in vitro and in unmethylated patient-derived GBM
xenografts. We subsequently investigated two human equivalent
TMZ doses in vivo, and demonstrated that 164mg/m2 was more
effective than 84mg/m2 as it led to (i) rapid and sustained tumour
shrinkage, and (ii) prolonged progression free and overall survival
in animals bearing patient-derived GBM with unmethylated MGMT
promoter. Finally, we found depleted MGMT mRNA levels in vitro
and in vivo to be associated with decreased NFκB/p65 nuclear
activation. The response to BTZ was in contrast to a second
proteasome inhibitor, carfilzomib, which was deemed unsuitable
for further investigation because it required high doses, did not kill
all GBM cell types, and/or killed the normal astrocytes more
efficiently, thus limiting its potential therapeutic window.
Dose intense TMZ treatment weakly attenuated expression of
MGMT protein in partially unmethylated T98G,7,33 but not fully
unmethylated P3 cells, consistent with previous findings where a
TMZ dose intense regimen was deemed marginally effective.34,35
Several clinical studies have explored blocking MGMT to improve
TMZ efficacy in treatment resistant GBM.36–39 Here, BTZ+TMZ
164mg/m2 combination treatment extended survival of mice-
bearing GBM with unmethylated MGMT promoter compared with
TMZ 164mg/m2 alone or a reduced dose BTZ+TMZ 82mg/m2
combination treatment. BTZ+TMZ 164mg/m2 treated tumours
exhibited reduced MGMT mRNA relative to untreated controls
(by 55%) and relative to TMZ 164mg/m2 (by 83%), providing
proof-of-concept that efficacy of the combination treatment
might be coincident with MGMT inhibition.
Several transcription factors have been implicated in regulating
MGMT expression, including NFκB.7,40 We demonstrated that
reduced NFκB activation was associated with decreased MGMT
protein and mRNA. In the canonical NF-κB pathway, p65/RelA
proteins are bound and localised to the cytoplasm by IκBα.
Phosphorylation of IκBα leads to its ubiquitination and proteaso-
mal degradation, which liberates active p65/RelA complexes,
allowing translocation to the nucleus and induction of gene
expression. BTZ or BTZ+TMZ combination treatment blocked
proteasome activity, and nuclear localisation of the phosphory-
lated and activated NFκB/p65 subunit became diminished, which
was associated with the lowest MGMT protein levels both in the
nucleus and total extracts. MGMT promoter methylation did not
change after BTZ or BTZ+TMZ combination treatment, implicating
NFκB/p65 in regulating MGMT mRNA and/or protein levels under
our treatment schedule.
Although the chymotryptic-like activity of β1 and β5 subunits
was effectively inhibited after 24 h by BTZ alone or in combination
with TMZ, MGMT levels at this time point were not reduced. Only
after treatment with BTZ for 48 h, was there a significant decrease
in MGMT levels, consistent with its stability and relatively long
half-life of ~60 h in promoter unmethylated cancer cells.41 Thus,
BTZ+TMZ 50 μM combination treatment for 48 h (in vitro
Bortezomib administered prior to temozolomide depletes MGMT,. . .
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Animals with tumour Animals without tumour
Fig. 4 Combination BTZ+TMZ treatment reduces tumour proliferation, angiogenesis and proteasome activity. (a) haematoxylin and eosin
(H&E) staining (insert: magnification ×200), (b) Ki67 staining (brown) and haematoxylin counterstain; and (c) CD31 staining for tumour
microvessels of tumour tissue from one representative animal from each of the treatment groups indicated. Magnification ×400; scale bars,
100 μm. Percentage mean ± S.E.M. of (d) Ki67-labelling index and (e) CD31 microvascular density in all animals. (f) Percent MGMT mRNA
expression in P3 GBM tumours after treatment in vivo. (g) Chymotryptic activity of β1 and β5 subunits of the 20S proteasome in brain tissue of
tumour-bearing mice treated with BTZ alone or BTZ+TMZ combination, measured as relative fluorescence units (RFU) of fluorophore 7-amino-
4-methylcoumarin (AMC) at 460 nm (n= 3 mice/group) (h) β1 and β5 chymotryptic activity in non-tumour-bearing brain tissue of untreated
control or BTZ treated mice (n= 3 mice/group). One-way ANOVA with Bonferroni correction for multiple testing, *P < 0.05, **P < 0.01 and
***P < 0.001
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sensitisation dose determined to be a quarter of the IC50 200 μM
TMZ dose) precisely induced O6-MeG adducts that could not be
repaired, as BTZ had effectively attenuated MGMT protein at this
time point. In contrast, treatment with higher combination dose
BTZ+TMZ 100 μM (half of the IC50 TMZ dose) generated more
MGMT protein than could be depleted via proteasomal blockade,
since activity of the β1 and β5 subunits was already partially
restored at 48 h. MGMT levels remained lower than in control or
TMZ treated cells, both in total and nuclear fractions.
The 20S proteasome activity returns to baseline within 72 h42
after BTZ treatment. A previous in vitro study reported BTZ
administered before TMZ was more effective in T98G, but not in
U87 cells where the reverse schedule was more effective.12
Although the authors did not allude to the reason for this, we
show here that was likely due to the advantage of first depleting
MGMT in the cells with unmethylated promoter, which thus
sensitises them to TMZ. U87 cells harbouring methylated MGMT
promoter respond better to TMZ and cannot be sensitised further,
as we demonstrated in vivo with BG7 cells with methylated
promoter. Furthermore, in our hands, 24 h was too early to see
decreased MGMT protein in response to BTZ 10 nM treatment.
BTZ treatment reduced tumour volumes compared with
untreated controls and marginally prolonged survival, indicating
that it crossed the BBB. LC–MS/MS detected greater concentra-
tions of the drug in the tumour-bearing compared with non-
tumour brains of treated animals, indicating that the disrupted
BBB43 contributes to improved penetrance. Furthermore, higher
concentrations were detected in animals sacrificed at earlier time
points. Although single agent BTZ marginally extended survival,
the best effect was achieved in combination with 164 mg/m2 TMZ.
This ability of BTZ to cross the BBB was previously demonstrated
in rat brains44 as well as in a pharmacokinetic study of clinical trial
enrolled patients where higher concentrations were measured in
the GBM tumour tissue than in the corresponding plasma.45
Newer generation proteasome inhibitors such as Ixazomib and
marizomib with improved BBB penetrance are now under
evaluation in phase I and III clinical trials, respectively.
Prolonged tumour growth stasis on MRI preceded extended
median survival in BTZ+TMZ 164mg/m2 treated animals relative
to TMZ monotherapy. Decreased tumour MGMT mRNA levels, as
well as catalytic activity of the β5 and β1 subunits were found in
tumours from these BTZ+TMZ 164mg/m2 treated animals,
confirming bioactivity and target inhibition at the orthotopic site.
In contrast, tumours treated with combination BTZ+TMZ at a
lower and less effective TMZ dose (82 mg/m2) expressed more
endogenous antioxidant enzymes and may represent a possible
mechanism of escape in vivo. This diminished efficacy of low dose
TMZ may also partially explain the less effective metronomic TMZ
doses investigated in clinical trials.17 Moreover, in some cancer
types, de novo synthesis of proteasome subunits may represent a
further mechanism of escape from proteasome blockade. Expres-
sion of the α4 and β1 subunits was significantly decreased in
animals responsive to combination BTZ+TMZ 164mg/m2. Indeed,
this was confirmed by reduced chymotryptic-like activity of
catalytic activity of the β5 and β1 subunits extracted from the
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Fig. 5 Detection of BTZ concentrations in mouse brains. Typical chromatograms in positive multiple reaction monitoring (MRM) mode for
Bortezomib in (a) vehicle control mouse brain tissue (b) vehicle control mouse brain tissue spiked with the BTZ analyte. (c) Mouse brain tissue
treated with BTZ 1.3 mg/m2 (on days 1, 4, 8, 11, for two cycles). Mean ± S.E.M. of BTZ tissue concentrations (ng/g) (d) in tumour-bearing mouse
brains, and (e) in control or BTZ- treated mouse brains without tumour. For single agent BTZ treatment, tumour-bearing mice were killed after
~40 days, the majority within 2 days after last BTZ dose. BTZ+TMZ combination treated mice were killed after ~100 days, 45 days after last BTZ
dose. Control non-tumour-bearing mice were untreated or treated on days 1, 4, 8, 11, for two cycles and killed 2 days after last BTZ dose. One-
way ANOVA with Bonferroni correction for multiple testing, **P < 0.01
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associated with susceptibility to lung cancer in GWAS studies and
shown to promote tumour cell proliferation.46 Diminished levels of
this subunit in the most responsive animals with prolonged
tumour doubling and decreased proliferation are consistent with
the improved antitumour responses.
Animals tolerated the treatments as their body weight was
stably maintained throughout the treatment until they suc-
cumbed to their disease. Furthermore, measures of platelet nadirs,
blood clotting time and the liver function enzymes, alanine and
aspartate aminotransferase, in plasma, were consistently normal-
ised, confirming that the treatment was safe and tolerated.
Although survival extension by 16% in mice-bearing TMZ resistant,
MGMT unmethylated GBM after BTZ+TMZ compared with TMZ
alone was modest, in a recurrent setting this might amount to
extended survival for this hard to treat patient group. Caution is
required in interpreting findings in mouse studies to humans;
however, clinical impact of this strategy will be evaluated in the
ongoing clinical trial (NCT0364354) for recurrent GBM patients.
Our findings in mice do realistically demonstrate the challenge of
treating GBM patients.
This is the first in vivo chemosensitisation at an orthotopic site
using patient-derived GBM cells with human equivalent doses of
BTZ and TMZ in a combination schedule. We demonstrated that
BTZ pre-treatment depleted MGMT and abrogated NFκB/
p65 signalling, thus accounting for improved sensitivity to TMZ.
Our sensitisation schedule may be of clinical relevance to improve
survival of GBM patients with unmethylated MGMT promoter.
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